PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective-Reference-Cited by-同舟云学术

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Published:2017-01-25 Issue:1 Volume:10 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Wang Jun,Yuan Ruirong,Song Wenru,Sun Jingwei,Liu Delong,Li Zihai

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-017-0403-5.pdf

Reference95 articles.

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci. 2013;342(6165):1432–3.

2. Pardoll D. Immunotherapy: it takes a village. Science. 2014;344(6180):149.

3. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91.

4. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.

5. Chen L. From the guest editor: Tumor site immune modulation therapy. Cancer J. 2014;20(4):254–5.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of novel radiolabeled antibody-conjugated graphene quantum dots for targeted in vivo breast cancer imaging and biodistribution studies;Arabian Journal of Chemistry;2024-02

2. Novel immune checkpoint targets: A promising therapy for cancer treatments;International Immunopharmacology;2024-01

3. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma;Cells;2023-12-22

4. Virus‐Like Nanotherapeutic for Spatiotemporally Enhancing Antigen Presentation and Cross‐Presentation toward Potential Personalized Immunotherapy;Advanced Healthcare Materials;2023-08-04

5. A membrane-associated MHC-I inhibitory axis for cancer immune evasion;Cell;2023-08